Aquestive Therapeutics Inc Total Assets
Aquestive Therapeutics Inc total assets. Based on the latest financial reports, Aquestive Therapeutics Inc (AQST) holds total assets worth $141.12 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see AQST market cap for the company's overall valuation and market capitalisation.
Total Assets of Aquestive Therapeutics Inc (2005–2025)
Total assets of Aquestive Therapeutics Inc from 2005 to 2025. This chart illustrates how Aquestive Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See AQST live share price for real-time trading data and today's change.
Aquestive Therapeutics Inc - Asset Composition Analysis
Aquestive Therapeutics Inc Total Assets Breakdown (December 2025)
Aquestive Therapeutics Inc total assets breakdown as of December 2025. Aquestive Therapeutics Inc's total assets of $141.12 Million consist of 93.1% current assets and 7.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 75.5% |
| Accounts Receivable | $17.76 Million | 11.1% |
| Inventory | $6.17 Million | 3.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2005–2025)
This chart illustrates how Aquestive Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of Aquestive Therapeutics Inc to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Aquestive Therapeutics Inc's current assets represent 93.1% of total assets in 2025, an increase from 18.7% in 2005.
- Cash Position: Cash and equivalents constituted 75.5% of total assets in 2025, up from 10.8% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 15.0% in 2005.
- Asset Diversification: The largest asset category is accounts receivable at 11.1% of total assets.
Aquestive Therapeutics Inc Competitors by Total Assets
Key competitors of Aquestive Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Sandoz Group AG
SW:SDZ
|
Switzerland | CHF22.86 Billion |
|
H Lundbeck A/S
CO:HLUN-B
|
Denmark | Dkr54.01 Billion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Viyash Scientific Limited
NSE:SEQUENT
|
India | Rs17.26 Billion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥5.11 Billion |
Aquestive Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.10 | 4.87 | 2.21 |
| Quick Ratio | 3.85 | 4.48 | 2.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $98.43 Million | $70.87 Million | $27.96 Million |
Aquestive Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Aquestive Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 14.15 |
| Latest Market Cap to Assets Ratio | 2.97 |
| Asset Growth Rate (YoY) | 58.2% |
| Total Assets | $160.43 Million |
| Market Capitalization | $476.77 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Aquestive Therapeutics Inc's assets at a significant premium (2.97x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Aquestive Therapeutics Inc's assets grew by 58.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Aquestive Therapeutics Inc (2005–2025)
The table below shows the annual total assets of Aquestive Therapeutics Inc from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $160.43 Million | +58.17% |
| 2024-12-31 | $101.42 Million | +76.64% |
| 2023-12-31 | $57.42 Million | +0.61% |
| 2022-12-31 | $57.07 Million | -7.94% |
| 2021-12-31 | $61.99 Million | -1.42% |
| 2020-12-31 | $62.88 Million | -19.87% |
| 2019-12-31 | $78.48 Million | -9.64% |
| 2018-12-31 | $86.85 Million | +101.44% |
| 2017-12-31 | $43.12 Million | +9.46% |
| 2016-12-31 | $39.39 Million | +44.92% |
| 2006-12-31 | $27.18 Million | +120.86% |
| 2005-12-31 | $12.31 Million | -- |
About Aquestive Therapeutics Inc
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulati… Read more